Equity · Healthcare
STOK
NASDAQStoke Therapeutics (STOK)
The line runs 31.32 USD on 13 August through 27.18 USD on 10 November, on a scale from 20 to 35. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.8B USD
- Revenue, year to Dec 2025
- 184.4M USD
- EPS, diluted, year to Dec 2025
- −0.12 USD
- 52-week range
- 22 USD – 38 USD
- Avg volume
- 55.0K
- Mentions, 30 days
- 1
as of Nov 10, 2026
Have Stoke Therapeutics (STOK) insiders bought or sold shares recently?
In the 90 days to 11 Nov 2026, Stoke Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 8 Oct 2025, show no open-market purchase.
Form 4, 90 days to 11 Nov 2026, newest reported trade 2 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | Ticho BarryCHIEF MEDICAL OFFICER | Sell | 7,195 | 190K USD |
| 02 Oct 2026 | Allan JonathanGENERAL COUNSEL & CORP SEC | Sell | 627 | 17K USD |
| 01 Oct 2026 | Ticho BarryCHIEF MEDICAL OFFICER | Sell | 1,051 | 27K USD |
| 01 Sep 2026 | Ticho BarryCHIEF MEDICAL OFFICER | Sell | 5,545 | 170K USD |
| 18 Aug 2026 | Allan JonathanGENERAL COUNSEL & CORP SEC | Sell | 2,861 | 92K USD |
| 18 Aug 2026 | Kaye Edward M. MDDirector | Sell | 12,567 | 403K USD |
| 18 Aug 2026 | Ticho BarryCHIEF MEDICAL OFFICER | Sell | 4,767 | 153K USD |
| Sold | 7 open-market sales | 34,613 | $1.05M |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 14 Aug 2026 | Allan JonathanGENERAL COUNSEL & CORP SEC | Option exercise | 6,000 | |
| 14 Aug 2026 | Kaye Edward M. MDDirector | Option exercise | 26,250 | |
| 14 Aug 2026 | Ticho BarryCHIEF MEDICAL OFFICER | Option exercise | 10,000 |
Which funds hold Stoke Therapeutics (STOK)?
7 of the 45 institutional funds we track reported a Stoke Therapeutics position for the quarter ended 30 Jun 2026 — a combined 139.2M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Held (±25%) | 3,336,697 | 109.2M USD | |
| Citadel Advisors | Added | 489,301 | 16.0M USD | +297.7% |
| Millennium Management | Trimmed | 261,028 | 8.5M USD | −44.7% |
| Two Sigma Investments | New position | 62,371 | 2.0M USD | |
| D. E. Shaw & Co. | Held (±25%) | 57,847 | 1.9M USD | +15.8% |
| AQR Capital Management | Trimmed | 26,449 | 865K USD | −43.1% |
| Balyasny Asset Management | Held (±25%) | 19,939 | 652K USD | −16.5% |
What has been filed or recorded for Stoke Therapeutics (STOK)?
The filings we hold for Stoke Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 145 shares | 4K USD notional · <0.001% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,917 shares | 126K USD notional · 0.008% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 5,459 shares | 142K USD notional · 0.008% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.08 USD | Revenue $11M |
| 30 Sep 2026 | Financials | Total assets | 406.7M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 352.6M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.93 USD | Revenue $9M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.79 USD | Revenue $6M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.12 USD | Revenue $184M |
| 31 Dec 2025 | Financials | Revenue | 184.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −6.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.12 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.65 USD | Revenue $11M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.40 USD | Revenue $14M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 1.90 USD | Revenue $159M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.65 USD | Revenue $37M |
What is Reddit saying about Stoke Therapeutics (STOK)?
Reddit mentioned STOK 1 times in the 30 days to 11 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 0% read bullish, 100% bearish and 0% neither. Reddit data updated 11 November 2026.
30-day window, Method
How do Reddit mentions of Stoke Therapeutics (STOK) compare with its price?
Share ↗
Which subreddits are talking about Stoke Therapeutics (STOK)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 1 | −0.10 |
What do people ask about Stoke Therapeutics (STOK)?
What did Stoke Therapeutics shares close at?27.18
Stoke Therapeutics closed at 27.18 USD on 10 Nov 2026, down 1.95% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Stoke Therapeutics’ market cap?1.8B
Stoke Therapeutics is worth 1.8B USD by market value as of 10 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Stoke Therapeutics’ revenue?184.4M
Stoke Therapeutics reported revenue of 184.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Stoke Therapeutics insiders bought or sold shares recently?7 sales
In the 90 days to 11 Nov 2026, Stoke Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 8 Oct 2025, show no open-market purchase. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Stoke Therapeutics?7 of 45
7 of the 45 funds we track reported a Stoke Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Citadel Advisors and Millennium Management. See Funds
When did Stoke Therapeutics last report earnings?−1.08
Stoke Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.08 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Stoke Therapeutics?0 mentions
Stoke Therapeutics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 0% read bullish and 100% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings